Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure.


Journal

Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608

Informations de publication

Date de publication:
11 2020
Historique:
received: 27 04 2020
revised: 31 08 2020
pubmed: 13 9 2020
medline: 23 9 2021
entrez: 12 9 2020
Statut: ppublish

Résumé

Risk stratification in chronic systolic heart failure (HF) is critical to identify the patients who may benefit from advanced therapies. It is aimed at identifying new biomarkers to improve prognosis evaluation and help to better understand HF physiopathology. Prognostic evaluation is performed in 198 patients with chronic systolic HF: 99 patients who died from cardiovascular cause within three years are individually matched for age, sex, and HF etiology (ischemic vs not) with 99 patients who are alive after three years of HF evaluation. A proteomic profiling of 15 apolipoproteins (Apo) is performed: Apo-A1, -A2, -A4, -B100, -C1, -C2, -C3, -C4, -D, -E, -F, -H, -J, -L1, and -M using LC-MRM-MS. In univariate analysis, the levels of Apo-B100 and -L1 are significantly lower and the levels of Apo-C1, -J, and -M are significantly higher in patients who died from cardiovascular cause as compared with patients alive. In the final statistical model, Apo-C1, Apo-J, and Apo-M improve individually the prediction of cardiovascular death. Ingenuity pathway analysis indicates these three Apo in a network associated with lipid metabolism, atherosclerosis signaling, and retinoid X receptor activation. Proteomic profiling of apolipoproteins using LC-MRM-MS might be useful in clinical practice for risk stratification of HF patients.

Identifiants

pubmed: 32918783
doi: 10.1002/prca.202000035
doi:

Substances chimiques

APOC1 protein, human 0
APOM protein, human 0
Apolipoprotein C-I 0
Apolipoproteins M 0
Biomarkers 0
CLU protein, human 0
Clusterin 0
Proteome 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2000035

Informations de copyright

© 2020 Wiley-VCH GmbH.

Références

E. Benjamin, M. Blaha, S. Chiuve, M. Cushman, S. Das, R. Deo, S. de Ferranti, J. Floyd, M. Fornage, C. Gillespie, C. Isasi, M. Jiménez, L. Jordan, S. Judd, D. Lackland, J. Lichtman, L. Lisabeth, S. Liu, C. Longenecker, R. Mackey, K. Matsushita, D. Mozaffarian, M. Mussolino, P. Muntner, A. H. A. S. C. and S. S. Subcommittee., Circulation 2017, 135, e146.
N. Lamblin, S. Ninni, O. Tricot, T. Meurice, G. Lemesle, C. Bauters, Open Heart 2020, 7, e001165.
P. S. Jhund, K. Macintyre, S. CR, J. D. Lewsey, S. Stewart, A. Redpath, J. W. Chalmers, S. Capewell, J. J. McMurray, Circulation 2009, 119, 515.
A. Mosterd, A. Hoes, Heart 2007, 93, 1137.
J. J. McMurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M. A. Gomez-Sanchez, T. Jaarsma, L. Kober, G. Y. Lip, A. P. Maggioni, A. Parkhomenko, B. M. Pieske, B. A. Popescu, A. Ronne, Eur. Heart J. 2012, 33, 1787.
A. H. Ouwerkerk, W. Voors, A. A. Zwinderman, JACC Heart Fail. 2014, 2, 429.
P. de Groote, J. Dagorn, B. Soudan, N. Lamblin, E. McFadden, C. Bauters, J. Am. Coll. Cardiol. 2004, 43, 1584.
G. Lemesle, F. Maury, O. Beseme, L. Ovart, P. Amouyel, N. Lamblin, P. de Groote, C. Bauters, F. Pinet, PLoS One 2015, 10, e0119265.
R. Amin, I. Muthuramu, J. P. Aboumsallem, M. Mishra, F. Jacobs, B. D.e Geest, Int. J. Mol. Sci. 2017, 18, 2012.
C. J. McNeal, S. Chatterjee, J. Hou, L. S. Worthy, C. D. Larner, R. D. Macfarlane, P. Alaupovic, R. W. Brocia, Cardiovasc. Res. 2013, 98, 83.
A. Basu, I. Bebu, A. J. Jenkins, J. A. Stoner, Y. Zhang, R. L. Klein, M. F. Lopes-Virella, W. T. Garvey, M. J. Budoff, P. Alaupovic, T. J. Lyons, J. Lipid Res. 2019, 60, 1432.
R. Pechlaner, S. Tsimikas, X. Yin, P. Willeit, F. Baig, P. Santer, F. Oberhollenzer, G. Egger, J. L. Witztum, V. J. Alexander, J. Willeit, S. Kiechl, M. Mayr, J. Am. Coll. Cardiol. 2017, 69, 789.
S. Roura, A. Gamez-Valero, J. Lupon, C. Galvez-Monton, F. E. Borras, A. Bayes-Genis, Lab. Invest. 2018, 98, 1291.
V. Blanchard, D. Garçon, C. Jaunet, K. Chemello, S. Billon-crossouard, A. Aguesse, A. Garfa, G. Famchon, A. Torres, C. L.e May, M. Pichelin, E. Bigot-corbel, G. Lambert, B. Cariou, S. Hadjadj, M. Krempf, K. Bach-ngohou, J. Lipid Res. 2020, 61, 1128.
P. de Groote, M. Fertin, C. Goéminne, G. Petyt, S. Peyrot, C. Foucher-Hossein, F. Mouquet, C. Bauters, N. Lamblin, Eur. Heart J. 2012, 33, 2672.
M. A. Kuzyk, D. Smith, J. Yang, T. J. Cross, A. M. Jackson, D. B. Hardie, N. L. Anderson, C. H. Borchers, Mol. Cell. Proteomics 2009, 8, 1860.
C. H. Chambers, A. G. Percy, A. J. Yang, J. Borchers, Mol. Cell. Proteomics 2015, 14, 3094.
S. Abbatiello, B. L. Ackermann, C. Borchers, R. A. Bradshaw, S. A. Carr, R. Chalkley, M. Choi, E. Deutsch, B. Domon, A. N. Hoofnagle, H. Keshishian, E. Kuhn, D. C. Liebler, M. MacCoss, B. MacLean, D. R. Mani, H. Neubert, D. Smith, L. Vitek, Mol. Cell. Proteomics 2017, 16, 327.
C. H. Percy, A. J. Chambers, A. G. Parker, C. E. Borchers, Methods Mol. Biol. 2013, 1000, 167.
C. H. Chambers, A. G. Percy, A. J. Yang, J. Camenzind, A. G. Borchers, Mol. Cell. Proteomics 2013, 12, 781.
C. H. Parker, C. E. Domanski, D. Percy, A. J. Chambers, A. G. Camenzind, A. G. Smith, D. S. Borchers, Top. Curr. Chem. 2014, 336, 117.
Y. Perez-Riverol, A. Csordas, J. Bai, M. Bernal-Llinares, S. Hewapathirana, D. Kundu, A. Inuganti, J. Griss, G. Mayer, M. Eisenacher, E. Pérez, J. Uszkoreit, J. Pfeuffer, T. Sachsenberg, S. Yilmaz, S. Tiwary, J. Cox, E. Audain, M. Walzer, A. Jarnuczak, A. Ternent, T. Brazma, J. Vizcaíno, Nucleic Acids Res. 2019, 47, D442.
E. Dubois, M. Fertin, J. Burdese, P. Amouyel, C. Bauters, F. Pinet, Proteomics: Clin. Appl. 2011, 5, 57.
A. Yoshihisa, Y. Kanno, S. Watanabe, T. Yokokawa, S. Abe, M. Miyata, T. Sato, S. Suzuki, M. Oikawa, A. Kobayashi, T. Yamaki, H. Kunii, K. Nakazato, H. Suzuki, T. Ishida, Y. Takeishi, Open Heart 2018, 5, e000730.
C. Jones, S. E. Jomary, Int. J. Biochem. Cell Biol. 2002, 34, 427.
K. Y. Deleon-Pennell, E. R. Ero, O. K. Ma, Y. Padmanabhan Iyer, R. Flynn, I. Espinoza, S. K. Musani, R. S. Vasan, M. E. Hall, E. R. Fox, M. L. Lindsey, ACS Omega 2019, 4, 1272.
A. Turkieh, M. Fertin, M. Bouvet, P. Mulder, H. Drobecq, G. Lemesle, N. Lamblin, P. De Groote, S. Porouchani, M. Chwastyniak, O. Beseme, P. Amouyel, F. Mouquet, J. L. Balligand, V. Richard, C. Bauters, F. Pinet, Circ.: Heart Failure 2018, 11, 1.
A. Turkieh, S. Porouchani, O. Beseme, M. Chwastyniak, P. Amouyel, N. Lamblin, J. Balligand, C. Bauters, F. Pinet, Cell Death Dis. 2019, 10, 608.
D. Rader, A. Bajaj, S. Khetarpal, J. Am. Coll. Cardiol. 2017, 69, 801.
S. A. Keshishian, H. Burgess, M. W. Gillette, M. A. Mertins, P. Clauser, K. R. Mani, D. R. Kuhn, E. W. Farrell, L. A. Gerszten, R. E. Carr, Mol. Cell. Proteomics 2015, 14, 2375.
S. Kay, R. G. Gregory, B. Grace, P. B. Pleasance, Rapid Commun. Mass Spectrom. 2007, 21, 2585.
Jones S. E., Jomary C., Int. J. Biochem. Cell Biol. 2002, 34, 427.
G. Liu, H. Zhang, F. Hao, J. Hao, L. Pan, Q. Zhao, J. Wo, Cell. Physiol. Biochem. 2018, 45, 1003.
Y. W. Hu, Z. P. Chen, X. M. Hu, J. Y. Zhao, J. L. Huang, X. Ma, S. F. Li, Y. R. Qiu, X. J. Wu, Y. H. Sha, J. J. Gao, Y. C. Wang, L. Zheng, Q. Wang, Apoptosis 2015, 20, 1321.
S. Hajny, C. Christoffersen, Int. J. Mol. Sci. 2017, 18, 1636.
S. Bjelosevic, D. Pascovici, H. Ping, V. Karlaftis, T. Zaw, X. Song, M. P. Molloy, P. Monagle, V. Ignjatovic, Mol. Cell. Proteomics 2017, 16, 924.
M. Mayr, R. Gerszten, S. Kiechl, J. Am. Coll. Cardiol. 2018, 71, 633.

Auteurs

Gilles Lemesle (G)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.
FACT, French Alliance for Cardiovascular Trials, Paris, F-75000, France.

Vincent Chouraki (V)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.

Pascal de Groote (P)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.

Annie Turkieh (A)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
FHU REMOD-HF.

Olivia Beseme (O)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
FHU REMOD-HF.

Hervé Drobecq (H)

CNRS UMR9017, Inserm U1019, CHU Lille, Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Univ. Lille, Lille, 59000, France.

Philippe Amouyel (P)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.

Nicolas Lamblin (N)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.
FHU REMOD-HF.

Christophe Bauters (C)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.
FHU REMOD-HF.

Florence Pinet (F)

CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.
FHU REMOD-HF.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH